

EC Meeting held on 08th FEBRUARY 2024 at 02:30 PM in the Seminar Room, Regional Institute of Ophthalmology, Kolkata-700014, West Bengal, India.

Following members were present in the meeting:

1. **Dr. Santanu Sen**
2. **Dr. Purban Ganguly**
3. **Dr. Manab Nandi**
4. **Dr. Lakshmi Kanta Mondal**
5. **Mr. Rajesh Arora**
6. **Mr. Rakesh Arora**
7. **Ms. Mandabi Bhattacharrya**
8. **Ms. Suparna Ray**

Determination of quorum- Quorum was complete with the presence of eight members.

Disclosure of Conflict of Interest: Chairman called for disclosure of Conflict of Interest (COI) in the protocols scheduled for deliberation in the meeting.

Reading and Approval of the minutes of the last meeting: The Chairperson presided over the discussion of the minutes of the meeting held on **08th February, 2024**. All members of the IEC approved the minutes.

1. **IRB Committee:** Establishment of an Institutional Scientific Review Committee/Board is essential to maintain the ethics for human safety, protection and proper rights and also to evaluate the safety, efficacy and patient-benefits of the drug. Proper medical management is also a major concern of this scientific board.

Sl No.	Agenda Item	Discussion	Action/ Recommendation	Responsibility	Target Date	Remarks
1	Dr. Lakshmi Kanta Mondal	Genetic Analysis of Ophthalmologic Disorders (Version No. 1.1, dated 29 Aug, 2023)	Dr. Lakshmi Kanta Mondal presented this study in details in Power Point Slides before the members of Ethics Committee.	After detailed discussion, all the members present in the meeting unanimously APPROVED the study to perform in its presented form.		Approved
2.	Dr. Tania Ray Bhadra	A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter,	Dr. Tania Ray Bhadra presented this study in details in Power Point Slides before the members of Ethics	After detailed discussion, all the members present in the meeting unanimously		Approved

	bioequivalence study with clinical endpoint comparing generic bimatoprost ophthalmic solution 0.01% and LUMIGAN® (bimatoprost ophthalmic solution) 0.01% in the treatment of subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.	Committee.	APPROVED the study to perform in its presented form.		
--	---	------------	--	--	--

P. Subangem
10/feb/2024

MEMBER SECRETARY
ETHICS COMMITTEE
R.I.O., KOLKATA-73